               SEQUENCE LISTING

<110> Affimed GmbH

<120> METHOD FOR THE PRODUCTION OF BISPECIFIC FCYRIII X CD30 ANTIBODY CONSTRUCTS

<130> A 3341PCT

<150> EP19219925.5
<151> 2019-12-27

<160> 21

<170> BiSSAP 1.3.6

<210> 1
<211> 5
<212> PRT
<213> Artificial Sequence


<220> 
<223> CDRH1

<400> 1
Ser Tyr Tyr Met His 
1               5   

<210> 2
<211> 17
<212> PRT
<213> Artificial Sequence


<220> 
<223> CDR H2

<400> 2
Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe Gln 
1               5                   10                  15      
Gly 
    

<210> 3
<211> 11
<212> PRT
<213> Artificial Sequence


<220> 
<223> CDR H3

<400> 3
Gly Ser Ala Tyr Tyr Tyr Asp Phe Ala Asp Tyr 
1               5                   10      

<210> 4
<211> 11
<212> PRT
<213> Artificial Sequence


<220> 
<223> CDR L1

<400> 4
Gly Gly His Asn Ile Gly Ser Lys Asn Val His 
1               5                   10      

<210> 5
<211> 9
<212> PRT
<213> Artificial Sequence


<220> 
<223> CDR L2

<400> 5
Gln Val Trp Asp Asn Tyr Ser Val Leu 
1               5                   

<210> 6
<211> 9
<212> PRT
<213> Artificial Sequence


<220> 
<223> CDR L3

<400> 6
Gln Val Trp Asp Asn Tyr Ser Val Leu 
1               5                   

<210> 7
<211> 5
<212> PRT
<213> Artificial Sequence


<220> 
<223> CDR H1

<400> 7
Thr Tyr Thr Ile His 
1               5   

<210> 8
<211> 17
<212> PRT
<213> Artificial Sequence


<220> 
<223> CDR H2

<400> 8
Tyr Ile Asn Pro Ser Ser Gly Tyr Ser Asp Tyr Asn Gln Asn Phe Lys 
1               5                   10                  15      
Gly 
    

<210> 9
<211> 14
<212> PRT
<213> Artificial Sequence


<220> 
<223> CDR H3

<400> 9
Arg Ala Asp Tyr Gly Asn Tyr Glu Tyr Thr Trp Phe Ala Tyr 
1               5                   10                  

<210> 10
<211> 11
<212> PRT
<213> Artificial Sequence


<220> 
<223> CDR L1

<400> 10
Lys Ala Ser Gln Asn Val Gly Thr Asn Val Ala 
1               5                   10      

<210> 11
<211> 7
<212> PRT
<213> Artificial Sequence


<220> 
<223> CDR L2

<400> 11
Ser Ala Ser Tyr Arg Tyr Ser 
1               5           

<210> 12
<211> 9
<212> PRT
<213> Artificial Sequence


<220> 
<223> CDR L3

<400> 12
Gln Gln Tyr His Thr Tyr Pro Leu Thr 
1               5                   

<210> 13
<211> 483
<212> PRT
<213> Artificial Sequence


<220> 
<223> CD16xCD30

<400> 13
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 
1               5                   10                  15      
Ser Leu Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 
            20                  25                  30          
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
        35                  40                  45              
Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe 
    50                  55                  60                  
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 
65                  70                  75                  80  
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      
Ala Arg Gly Ser Ala Tyr Tyr Tyr Asp Phe Ala Asp Tyr Trp Gly Gln 
            100                 105                 110         
Gly Thr Leu Val Thr Val Ser Ser Gly Gly Ser Gly Gly Ser Gly Gly 
        115                 120                 125             
Ser Asp Ile Val Met Thr Gln Ser Pro Lys Phe Met Ser Thr Ser Val 
    130                 135                 140                 
Gly Asp Arg Val Thr Val Thr Cys Lys Ala Ser Gln Asn Val Gly Thr 
145                 150                 155                 160 
Asn Val Ala Trp Phe Gln Gln Lys Pro Gly Gln Ser Pro Lys Val Leu 
                165                 170                 175     
Ile Tyr Ser Ala Ser Tyr Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr 
            180                 185                 190         
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln 
        195                 200                 205             
Ser Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr His Thr Tyr Pro 
    210                 215                 220                 
Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Asn Gly Gly Ser Gly 
225                 230                 235                 240 
Gly Ser Gly Gly Ser Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu 
                245                 250                 255     
Ala Arg Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr 
            260                 265                 270         
Thr Phe Thr Thr Tyr Thr Ile His Trp Val Arg Gln Arg Pro Gly His 
        275                 280                 285             
Asp Leu Glu Trp Ile Gly Tyr Ile Asn Pro Ser Ser Gly Tyr Ser Asp 
    290                 295                 300                 
Tyr Asn Gln Asn Phe Lys Gly Lys Thr Thr Leu Thr Ala Asp Lys Ser 
305                 310                 315                 320 
Ser Asn Thr Ala Tyr Met Gln Leu Asn Ser Leu Thr Ser Glu Asp Ser 
                325                 330                 335     
Ala Val Tyr Tyr Cys Ala Arg Arg Ala Asp Tyr Gly Asn Tyr Glu Tyr 
            340                 345                 350         
Thr Trp Phe Ala Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
        355                 360                 365             
Gly Gly Ser Gly Gly Ser Gly Gly Ser Ser Tyr Val Leu Thr Gln Pro 
    370                 375                 380                 
Ser Ser Val Ser Val Ala Pro Gly Gln Thr Ala Thr Ile Ser Cys Gly 
385                 390                 395                 400 
Gly His Asn Ile Gly Ser Lys Asn Val His Trp Tyr Gln Gln Arg Pro 
                405                 410                 415     
Gly Gln Ser Pro Val Leu Val Ile Tyr Gln Asp Asn Lys Arg Pro Ser 
            420                 425                 430         
Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr 
        435                 440                 445             
Leu Thr Ile Ser Gly Thr Gln Ala Met Asp Glu Ala Asp Tyr Tyr Cys 
    450                 455                 460                 
Gln Val Trp Asp Asn Tyr Ser Val Leu Phe Gly Gly Gly Thr Lys Leu 
465                 470                 475                 480 
Thr Val Leu 
            

<210> 14
<211> 120
<212> PRT
<213> Artificial Sequence


<220> 
<223> VH CD16

<400> 14
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 
1               5                   10                  15      
Ser Leu Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 
            20                  25                  30          
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
        35                  40                  45              
Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe 
    50                  55                  60                  
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 
65                  70                  75                  80  
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      
Ala Arg Gly Ser Ala Tyr Tyr Tyr Asp Phe Ala Asp Tyr Trp Gly Gln 
            100                 105                 110         
Gly Thr Leu Val Thr Val Ser Ser 
        115                 120 

<210> 15
<211> 106
<212> PRT
<213> Artificial Sequence


<220> 
<223> VL CD16

<400> 15
Ser Tyr Val Leu Thr Gln Pro Ser Ser Val Ser Val Ala Pro Gly Gln 
1               5                   10                  15      
Thr Ala Thr Ile Ser Cys Gly Gly His Asn Ile Gly Ser Lys Asn Val 
            20                  25                  30          
His Trp Tyr Gln Gln Arg Pro Gly Gln Ser Pro Val Leu Val Ile Tyr 
        35                  40                  45              
Gln Asp Asn Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser 
    50                  55                  60                  
Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met 
65                  70                  75                  80  
Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Asn Tyr Ser Val Leu 
                85                  90                  95      
Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 
            100                 105     

<210> 16
<211> 106
<212> PRT
<213> Artificial Sequence


<220> 
<223> VH CD30

<400> 16
Ser Tyr Val Leu Thr Gln Pro Ser Ser Val Ser Val Ala Pro Gly Gln 
1               5                   10                  15      
Thr Ala Thr Ile Ser Cys Gly Gly His Asn Ile Gly Ser Lys Asn Val 
            20                  25                  30          
His Trp Tyr Gln Gln Arg Pro Gly Gln Ser Pro Val Leu Val Ile Tyr 
        35                  40                  45              
Gln Asp Asn Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser 
    50                  55                  60                  
Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met 
65                  70                  75                  80  
Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Asn Tyr Ser Val Leu 
                85                  90                  95      
Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 
            100                 105     

<210> 17
<211> 107
<212> PRT
<213> Artificial Sequence


<220> 
<223> VL CD30

<400> 17
Asp Ile Val Met Thr Gln Ser Pro Lys Phe Met Ser Thr Ser Val Gly 
1               5                   10                  15      
Asp Arg Val Thr Val Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Asn 
            20                  25                  30          
Val Ala Trp Phe Gln Gln Lys Pro Gly Gln Ser Pro Lys Val Leu Ile 
        35                  40                  45              
Tyr Ser Ala Ser Tyr Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly 
    50                  55                  60                  
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser 
65                  70                  75                  80  
Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr His Thr Tyr Pro Leu 
                85                  90                  95      
Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Asn 
            100                 105         

<210> 18
<211> 8
<212> PRT
<213> Artificial Sequence


<220> 
<223> C-terminal CD16A

<400> 18
Ser Phe Phe Pro Pro Gly Tyr Gln 
1               5               

<210> 19
<211> 192
<212> PRT
<213> Homo sapiens


<400> 19
Gly Met Arg Thr Glu Asp Leu Pro Lys Ala Val Val Phe Leu Glu Pro 
1               5                   10                  15      
Gln Trp Tyr Arg Val Leu Glu Lys Asp Ser Val Thr Leu Lys Cys Gln 
            20                  25                  30          
Gly Ala Tyr Ser Pro Glu Asp Asn Ser Thr Gln Trp Phe His Asn Glu 
        35                  40                  45              
Ser Leu Ile Ser Ser Gln Ala Ser Ser Tyr Phe Ile Asp Ala Ala Thr 
    50                  55                  60                  
Val Asp Asp Ser Gly Glu Tyr Arg Cys Gln Thr Asn Leu Ser Thr Leu 
65                  70                  75                  80  
Ser Asp Pro Val Gln Leu Glu Val His Ile Gly Trp Leu Leu Leu Gln 
                85                  90                  95      
Ala Pro Arg Trp Val Phe Lys Glu Glu Asp Pro Ile His Leu Arg Cys 
            100                 105                 110         
His Ser Trp Lys Asn Thr Ala Leu His Lys Val Thr Tyr Leu Gln Asn 
        115                 120                 125             
Gly Lys Gly Arg Lys Tyr Phe His His Asn Ser Asp Phe Tyr Ile Pro 
    130                 135                 140                 
Lys Ala Thr Leu Lys Asp Ser Gly Ser Tyr Phe Cys Arg Gly Leu Phe 
145                 150                 155                 160 
Gly Ser Lys Asn Val Ser Ser Glu Thr Val Asn Ile Thr Ile Thr Gln 
                165                 170                 175     
Gly Leu Ala Val Ser Thr Ile Ser Ser Phe Phe Pro Pro Gly Tyr Gln 
            180                 185                 190         



<210> 20
<211> 6
<212> PRT
<213> Artificial Sequence


<220> 
<223> His tag

<400> 20
His His His His His His 
1               5       

<210> 21
<211> 9
<212> PRT
<213> Artificial Sequence


<220> 
<223> linker

<400> 21
Gly Gly Ser Gly Gly Ser Gly Gly Ser 
1               5                   

